Integration of Darolutamide in the Treatment Landscape for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis of Efficacy and Safety
We compared different medical treatment options for metastatic hormone-sensitive prostate cancer, with a special focus on a drug called darolutamide. Darolutamide is well tolerated and is effective, particularly in patients with a low volume of metastasis and patients with other health conditions that may limit their treatment options.
Authors
- Michael Ladurner (ORCID: https://orcid.org/0000-0003-2396-9175)
- Mona Kafka (ORCID: https://orcid.org/0000-0003-4775-948X)
- Hannes Neuwirt (ORCID: https://orcid.org/0000-0003-1064-0098)
- Jasmin Bektić (ORCID: https://orcid.org/0000-0003-3946-0840)
- Felix Keller (ORCID: https://orcid.org/0000-0002-8240-7255)
- Isabel Heidegger (ORCID: https://orcid.org/0000-0003-1517-5746)
- Nastasiia Artamonova (ORCID: https://orcid.org/0009-0008-8260-9501)
- Wolfgang Horninger
- Felix Melchior (ORCID: https://orcid.org/0000-0002-7489-8381)
- Giulia Giannini (ORCID: https://orcid.org/0009-0007-3241-3183)
- Magdalena Koett
Institutions
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
Publication Details
- Journal
- European Urology Open Science
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1016/j.euros.2025.11.011
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00